News
Oncternal Therapeutics Q1 2024 GAAP EPS $(2.83) Beats $(2.88) Estimate, Sales $569.000K Beat $176.667K Estimate
9 May 24
Earnings, Earnings Beats, News
Oncternal Announces First Patient Dosed In Fourth Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
18 Apr 24
Biotech, News, General
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $28
15 Apr 24
News, Price Target, Analyst Ratings
Insiders Buying Westlake Chemical Partners And 2 Other Stocks
2 Apr 24
Long Ideas, News, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
Recap: Oncternal Therapeutics Q4 Earnings
7 Mar 24
Earnings
Oncternal Therapeutics Q4 2023 GAAP EPS $(3.110) Misses $(3.070) Estimate, Sales $297.000K Beat $137.500K Estimate
7 Mar 24
Earnings, Earnings Beats, Earnings Misses, News
Earnings Scheduled For March 7, 2024
7 Mar 24
Earnings
Oncternal Therapeutics's Earnings: A Preview
6 Mar 24
Earnings
Press releases
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
2 May 24
Press Releases
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
18 Apr 24
Press Releases
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
15 Mar 24
News, Health Care, Press Releases
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
Earnings, Press Releases